Alamar Biosciences

Q2 FY2026 EarningsQ2 FY26 results beat consensus across all major financial metrics: total revenue of $29.4M exceeded the $25.9M estimate, while GAAP EPS of -$0.22 was significantly better than the -$0.33 expected. Gross margin reached 60.2%, surpassing the 56.0% consensus due to manufacturing efficiencies and a favorable shift toward high-margin consumables, which grew 147% YoY. Following a successful April IPO, the company maintains a robust cash position of $250.1M to fund its commercial expansion and the development of the ARGO HT/DX diagnostic platform.